European Commission predicts issuing recast proposals in early 2012; key EU committee created
This article was originally published in RAJ Devices
European Commission proposals for the recast of the EU directives on medical devices, active implantable medical devices and in vitro diagnostics could be finalised by the beginning of 20121. In the meantime, another endeavour to have emerged from the recast deliberations has taken a step forward, after member states set up a Central Management Committee (CMC) that they envisage will support the resources-challenged commission in ensuring consistency in the implementation of the legal requirements throughout the EU.
You may also be interested in...
Filing for clinical trial activities in the electronic common technical document format via the Common Electronic Submission Gateway is expected to help sponsors send their information in a secure manner, with reduced transmission times and cost.
Roche hopes that its investigational drug satralizumab for neuromyelitis optica spectrum disorder will win EU approval in the second half of 2020.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).